Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma

Santanu Dasgupta, Pulak K. Tripathi, Hongxing Qin, Malaya Bhattacharya-Chatterjee, Joseph Valentino, Sunil K. Chatterjee

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


To identify molecular targets for immunotherapy of head and neck squamous cell carcinoma (HNSCC) patients, we analyzed gene expression profile in matched tumor (HN) and normal fibroblast (FB) cell lines established from a HNSCC patient using microarray technique followed by real-time RT-PCR. Screening against a series of established normal and malignant cell lines followed by screening against a panel of normal human tissues led to the identification of 7 genes (AREG, CDH3, KLK10, NmU, SLPI, ANAX3 and MAL2), which were over-expressed at least 10-fold in tumors over any of the normal tissues. We determined the expression of mRNA encoding these genes against a panel of 15 HNSCC primary tumor samples. Relative expression of these genes was at least 20-fold. Expression of AREG, CDH3, KLK10, NmU and SLPI at the protein level was determined by immunohistochemistry in seven supraglottic laryngeal cancer specimens. All five proteins were expressed in these tumor samples with high intensity. We conclude that these molecules are potential targets for immunotherapy of HNSCC patients.

Original languageEnglish
Pages (from-to)306-316
Number of pages11
JournalOral Oncology
Issue number3
StatePublished - Mar 2006

Bibliographical note

Funding Information:
This study was supported by NIH grant RO1 CA 89748. We dedicate this publication to the memory of our colleague Honxing Qin. We thank Dr. E. P. Diamandis (University of Toronto, Canada) for kind gift of the anti-KLK10 antibody.


  • Head and neck cancer
  • Immunotherapy
  • Microarray
  • Overexpressed genes
  • Real-time RT-PCR

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research


Dive into the research topics of 'Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma'. Together they form a unique fingerprint.

Cite this